Even a 510% reduction in body weight is associated with meaningful reductions in cardiometabolic risk, yet lifestyle interventions alone often fail to achieve or sustain this level of loss in realworld settings
CMS data from 2023 puts the overturn rate at roughly 41 percent for commercial denials when patients file a level-1 internal appeal with new clinical documentation
S-adenosyl homocysteine (SAH), a by-product of methylation reactions, is then hydrolyzed to homocysteine
Retatrutide for the Treatment of Obesity, Obstructive Sleep Apnea and Knee Osteoarthritis: Rationale and Design of the TRIUMPH Registrational Clinical Trials
doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review